MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s40121-020-00329-y

Медицинская библиотека · Infectious diseases and therapy · 2020

Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study.

Atsukawa Masanori, Tsubota Akihito, Kondo Chisa, Toyoda Hidenori, Nakamuta Makoto, Takaguchi Koichi, Watanabe Tsunamasa, Hiraoka Atsushi, Uojima Haruki, Ishikawa Toru, Iwasa Motoh, Tada Toshifumi, Nozaki Akito, Chuma Makoto, Fukunishi Shinya, Asai Akira, Asano Toru, Ogawa Chikara, Abe Hiroshi, Hotta Naoki, Shima Toshihide, Iio Etsuko, Mikami Shigeru, Tachi Yoshihiko, Fujioka Shinichi, Okubo Hironao, Shimada Noritomo, Tani Joji, Hidaka Isao, Moriya Akio, Tsuji Kunihiko, Akahane Takehiro, Yamashita Naoki, Okubo Tomomi, Arai Taeang, Morita Kiyoshi, Kawata Kazuhito, Tanaka Yasuhito, Okanoue Takeshi, Maeda Shin, Kumada Takashi, Iwakiri Katsuhiko, KTK49 Liver Study Group

СтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

Clinical trials of direct-acting antivirals for patients with decompensated cirrhosis have been conducted, but there is limited information on the medicinal applications in clinical settings. We aimed to evaluate the safety and efficacy of sofosbuvir/velpatasvir for decompensated cirrhotic patients with genotypes 1 and 2 in real-world clinical practice.

METHODS

A prospective, multicenter study of 12-week sofosbuvir/velpatasvir was conducted for patients with decompensated cirrhosis at 33 institutions.

RESULTS

The cohort included 71 patients (52 genotype 1, 19 genotype 2): 7 with Child-Pugh class A, 47 with class B, and 17 with class C (median score 8; range 5-13). The albumin-bilirubin (ALBI) score ranged from - 3.01 to - 0.45 (median - 1.58). Sixty-nine patients (97.2%) completed treatment as scheduled. The overall rate of sustained virologic response at 12 weeks post-treatment (SVR12) was 94.4% (67/71). SVR12 rates in the patients with Child-Pugh classes A, B, and C were 85.7%, 97.9%, and 88.2%, respectively. Among 22 patients with a history of hepatocellular carcinoma treatment, 20 (90.9%) achieved SVR12. The Child-Pugh score and ALBI grade significantly improved after achieving SVR12 (p = 7.19 × 10-4 and 2.42 × 10-4, respectively). Notably, the use of diuretics and branched-chain amino acid preparations significantly reduced after achieving SVR12. Adverse events were observed in 19.7% of the patients, leading to treatment discontinuation in two patients with cholecystitis and esophageal varices rupture, respectively.

CONCLUSION

Twelve weeks of sofosbuvir/velpatasvir in real-world clinical practice yielded high SVR rates and acceptable safety profiles in decompensated cirrhotic patients with genotypes 1 and 2. Achievement of SVR not only restored the liver functional reserve but also reduced or spared the administration of drugs for related complications.

TRIAL REGISTRATION: UMIN registration no, 000038587.

Для цитирования: Atsukawa Masanori, Tsubota Akihito, Kondo Chisa, Toyoda Hidenori, Nakamuta Makoto, Takaguchi Koichi, Watanabe Tsunamasa, Hiraoka Atsushi, Uojima Haruki, Ishikawa Toru, Iwasa Motoh, Tada Toshifumi, Nozaki Akito, Chuma Makoto, Fukunishi Shinya, Asai Akira, Asano Toru, Ogawa Chikara, Abe Hiroshi, Hotta Naoki, Shima Toshihide, Iio Etsuko, Mikami Shigeru, Tachi Yoshihiko, Fujioka Shinichi, Okubo Hironao, Shimada Noritomo, Tani Joji, Hidaka Isao, Moriya Akio, Tsuji Kunihiko, Akahane Takehiro, Yamashita Naoki, Okubo Tomomi, Arai Taeang, Morita Kiyoshi, Kawata Kazuhito, Tanaka Yasuhito, Okanoue Takeshi, Maeda Shin, Kumada Takashi, Iwakiri Katsuhiko, KTK49 Liver Study Group. Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study.. Infectious diseases and therapy. 2020. DOI: 10.1007/s40121-020-00329-y.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.